Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125038772 | 12503877 | 2 | F | 20160720 | 20160628 | 20160722 | EXP | PHJP2016JP018082 | NOVARTIS | MURASAWA C. ASSESSMENT OF EVEROLIMUS ADMINISTRATION FOR ADVANCED RECURRENT BREAST CANCER. THE 24TH ANNUAL MEETING OF THE JAPANESE BREAST CANCER SOCIETY. 2016 | 45.00 | YR | F | Y | 0.00000 | 20160722 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125038772 | 12503877 | 1 | PS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, UNK | 22334 | 10 | MG | TABLET | |||||||
| 125038772 | 12503877 | 2 | C | EXEMESTANE. | EXEMESTANE | 1 | Unknown | 25 MG, UNK | 0 | 25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125038772 | 12503877 | 1 | Breast cancer recurrent |
| 125038772 | 12503877 | 2 | Breast cancer recurrent |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125038772 | 12503877 | OT |
| 125038772 | 12503877 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125038772 | 12503877 | Death | |
| 125038772 | 12503877 | Renal failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |